Drugs / 64Cu-PORPHYSOMES
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06977126 | Nov 2025 → Nov 2026 expected | female reproductive organ cancer | University Health Network, Toronto | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 64Cu-PORPHYSOMES | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06977126 ↗ |
| Known as | 64Cu-PS | “64Cu-PORPHYSOMES (64Cu-PS, pegylated Copper-64 labelled porphyrin-lipid conjugate-containing nanoparticle suspension)” NCT06977126 ↗ |
| Modality | Diagnostic / imaging agent | “for PET/CT imaging assessments” NCT06977126 ↗ |
| Route | Intravenous | “by intravenous (IV) route” NCT06977126 ↗ |